Keros Therapeutics Inc
KROSHealthcare|Biotechnology|USA
$11.80
-0.23 (-1.91%)
Tangible Book
$14.48
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05975905 A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). | Pulmonary Arterial Hypertension | P2 | Terminated | 113 | RCT, Double-blind | Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks |
| NCT05927012 A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). | Iron Deficiency Anemia | P2 | Withdrawn | — | Open-label | KER-047 |